Efficacy of a novel class of RNA interference therapeutic agents.

ABSTRACT: RNA interference (RNAi) is being widely used in functional gene research and is an important tool for drug discovery. However, canonical double-stranded short interfering RNAs are unstable and induce undesirable adverse effects, and thus there is no currently RNAi-based therapy in the clinic. We have developed a novel class of RNAi agents, and evaluated their effectiveness in vitro and in mouse models of acute lung injury (ALI) and pulmonary fibrosis. The novel class of RNAi agents (nkRNA®, PnkRNA™) were synthesized on solid phase as single-stranded RNAs that, following synthesis, self-anneal into a unique helical structure containing a central stem and two loops. They are resistant to degradation and suppress their target genes. nkRNA and PnkRNA directed against TGF-?1mRNA ameliorate outcomes and induce no off-target effects in three animal models of lung disease. The results of this study support the pathological relevance of TGF-?1 in lung diseases, and suggest the potential usefulness of these novel RNAi agents for therapeutic application.

SUBMITTER: Hamasaki T 

PROVIDER: S-EPMC3419724 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature